ReviewInvestigational new drugs1997
Matrix metalloproteinase inhibitors: present achievements and future prospects.
Review in Investigational new drugs, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- New Derivatives ofInternational journal of molecular sciences · 2023Article
- Microwave-Assisted Facile Synthesis, Anticancer Evaluation and Docking Study of N-((5-(Substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) Benzamide Derivatives.Molecules (Basel, Switzerland) · 2017Article
- Article
- Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors.Chemical biology & drug design · 2011Article
- POVME: an algorithm for measuring binding-pocket volumes.Journal of molecular graphics & modelling · 2011Article
- A cancer cell metalloprotease triad regulates the basement membrane transmigration program.Genes & development · 2006Article
- Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2003Article
- Article
- Current approaches and future strategies for pancreatic carcinoma.Investigational new drugs · 2000Review
- Development of target-based antineoplastic agents.Investigational new drugs · 2000Review
- Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.Clinical & experimental metastasis · 2000Article
- [Anti-angiogenesis: a new approach to tumor therapy?].Medizinische Klinik (Munich, Germany : 1983) · 1999Article
- Oscillatory behavior of a simple kinetic model for proteolysis during cell invasion.Biophysical journal · 1999Article
- Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer.Clinical & experimental metastasis · 1999Article
- Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 1999Review
- Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.The American journal of pathology · 1998Article
- Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.Journal of molecular recognition : JMRArticle
- Calcification and identification of metalloproteinases in bovine pericardium after subcutaneous implantation in rats.Journal of materials science. Materials in medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs) are a class of structurally related enzymes that function in the degradation of extracellular matrix proteins that constitute the pericellular connective tissue and play an important role in both normal and pathological tissue remodelling. Increased MMP activity is detected in a wide range of cancers and seems correlated to their invasive and metastatic potential. MMPs thus seem an attractive target for both diagnostic and therapeutic purposes. Several synthetic matrix metalloproteinase inhibitors (MMPIs) are currently being developed. Preclinical studies are promising as they suggest inhibition of several steps in the metastatic process. Marimastat is the first MMPI to enter comparative phase III trials after early clinical trials established the safety profile. Clinical trials will need to be specifically designed to optimally evaluate the therapeutic potential of this novel class of cytostatic drugs. Safety studies should consider the markedly different toxicity profile and determine the range of biologically active dosage, while efficacy studies should be performed in selected clinical settings with appropriate end-points. We review the present achievements in preclinical and clinical studies with MMPIs, discuss specific considerations for appropriate study design and reflect on the future prospects of this novel class of agents.
Indexed as
Identifiers
9387040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.